Evidence map›Paper›PMID 23462180›Full record

ArticleGastroenterology2013

A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication.

Dahlene N Fusco, Cynthia Brisac, Sinu P John, Yi-Wen Huang, Christopher R Chin, Tiao Xie, Hong Zhao, Nikolaus Jilg, Leiliang Zhang, Stephane Chevaliez and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Identification of AMOTL2 as an antiviral factor that enhances the human type I interferon response against Zika virus.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. IFN-β: A Contentious Player in Host-Pathogen Interaction in Tuberculosis.International journal of molecular sciences · 2017
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 4 countries.

Dahlene N FuscoGastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Cynthia Brisac
Sinu P John
Yi-Wen Huang
Christopher R Chin
Tiao Xie
Hong Zhao
Nikolaus Jilg
Leiliang Zhang
Stephane Chevaliez
Daniel Wambua
Wenyu Lin
Lee Peng
Raymond T Chung
Abraham L Brass
Massachusetts General Hospital · USChinese Academy of Medical Sciences & Peking Union Medical College · CNHarvard University · USNational Institute of Allergy and Infectious Diseases · USPeking University First Hospital · CNRagon Institute of MGH, MIT and Harvard · USTaipei Medical University · TWUniversité Paris-Est Créteil · FRUniversity of Massachusetts Chan Medical School · US

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG · 1991 to 2026
$35.3M
The Role of IFITM3 in the Anti-viral Host ResponseR01AI091786 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BRASS, ABRAHAM L · 2011 to 2015
$2.1M
NIAID NIH HHS 1R01AI091786NIAID NIH HHS R01 AI091786NIAID NIH HHS U19 AI082630NIDDK NIH HHS P30 DK043351
6 · The paper itself

Abstract

BACKGROUND &

aimsHepatitis C virus (HCV) infection is a leading cause of end-stage liver disease. Interferon-α (IFNα) is an important component of anti-HCV therapy; it up-regulates transcription of IFN-stimulated genes, many of which have been investigated for their antiviral effects. However, all of the genes required for the antiviral function of IFNα (IFN effector genes [IEGs]) are not known. IEGs include not only IFN-stimulated genes, but other nontranscriptionally induced genes that are required for the antiviral effect of IFNα. In contrast to candidate approaches based on analyses of messenger RNA (mRNA) expression, identification of IEGs requires a broad functional approach.

methodsWe performed an unbiased genome-wide small interfering RNA screen to identify IEGs that inhibit HCV. Huh7.5.1 hepatoma cells were transfected with small interfering RNAs incubated with IFNα and then infected with JFH1 HCV. Cells were stained using HCV core antibody, imaged, and analyzed to determine the percent infection. Candidate IEGs detected in the screen were validated and analyzed further.

resultsThe screen identified 120 previously unreported IEGs. From these, we more fully evaluated the following: asparagine-linked glycosylation 10 homolog (yeast, α-1,2-glucosyltransferase); butyrylcholinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2); glucokinase (hexokinase 4) regulator; guanylate cyclase 1, soluble, β 3; MYST histone acetyltransferase 1; protein phosphatase 3 (formerly 2B), catalytic subunit, β isoform; peroxisomal proliferator-activated receptor-γ-DBD-interacting protein 1; and solute carrier family 27 (fatty acid transporter), member 2; and demonstrated that they enabled IFNα-mediated suppression of HCV at multiple steps of its life cycle. Expression of these genes had more potent effects against flaviviridae because a subset was required for IFNα to suppress dengue virus but not influenza A virus. In addition, many of the host genes detected in this screen (92%) were not transcriptionally stimulated by IFNα; these genes represent a heretofore unknown class of non-IFN-stimulated gene IEGs.

conclusionsWe performed a whole-genome loss-of-function screen to identify genes that mediate the effects of IFNα against human pathogenic viruses. We found that IFNα restricts HCV via actions of general and specific IEGs.

Indexed as

Antiviral AgentsHepacivirusHepatitis CHumansInterferon-alphaRNA, ViralVirus ReplicationAntiviral AgentsInterferon-alphaRNA, Viral

Identifiers

PMID23462180
PMCPMC3665646
OpenAlexW2084604444

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.